NCT07557225 18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
| NCT ID | NCT07557225 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking University First Hospital |
| Condition | Clear Cell Renal Cell Cancer (ccRCC) |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2026-04-27 |
| Primary Completion | 2028-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 200 participants in total. It began in 2026-04-27 with a primary completion date of 2028-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to evaluate the diagnostic value of CAIX protein specific probe 18F-T2 in PET/CT imaging in participants with solid tumors. It will also assess the safety, tolerability and radiation dosimetry of 18F-T2.
Eligibility Criteria
Inclusion Criteria: All participants must meet the following criteria: 1. Written and voluntarily given Informed Consent. 2. Male or female ≥18 years of age at time of consent. 3. Have the capacity to understand the study and be willing and able to comply with all protocol requirements. 4. Participants with histologically confirmed or suspected tumors of the following types, but not limited to: Clear Cell Renal Cell Cancer; Urothelial Carcinoma; Colorectal Cancer; Cervical Cancer; Ovarian Cancer; Head and Neck Cancer; Hepatocellular Carcinoma; Cholangiocarcinoma; Non Small Cell Lung Cancer; Small Cell Lung Cancer; Breast Cancer; Pancreatic Cancer; Endometrial Cancer; Von Hippel Lindau Disease. Exclusion Criteria: Participants will be excluded from participation in the study if one or more of the following criteria are met: 1. Have any serious non-malignant disease (e.g., psychiatric, infectious, autoimmune or metabolic) that may interfere with the objectives of the study or with the safety or compliance of the participant, as judged by the Investigator. 2. Have a mental impairment that may compromise the ability to give Informed Consent and comply with the requirements of the study. 3. Be a female who is pregnant or breastfeeding.
Contact & Investigator
Meng Liu
PRINCIPAL INVESTIGATOR
Peking University First Hospital
Frequently Asked Questions
Who can join the NCT07557225 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Clear Cell Renal Cell Cancer (ccRCC). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07557225 currently recruiting?
Yes, NCT07557225 is actively recruiting participants. Contact the research team at 1910301229@pku.edu.cn for enrollment information.
Where is the NCT07557225 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT07557225 clinical trial?
NCT07557225 is sponsored by Peking University First Hospital. The principal investigator is Meng Liu at Peking University First Hospital. The trial plans to enroll 200 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.